Key facts
- SymphoRNA’s last known valuation is $98.4M.
- It has raised $49.2M; the latest was Later Stage VC ($13.2M) in Nov 2024.
- Notable investors include Global Brain, MicroVentures, Lowercarbon Capital, Balderton Capital, Redalpine — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for SymphoRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for SymphoRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SymphoRNA
Operator of a novel cultivated-protein production process designed to create animal-cell-derived meat without conventional livestock. The company offers an RNA-based reprogramming technology along with non-GMO cell-engineering and scalable pilot manufacturing, enabling food producers and ingredient manufacturers to bring meat products to market more efficiently.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 11
- Website
- symphorna.com/
- Ownership
- Privately Held (backing)
SymphoRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SymphoRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SymphoRNA in its N-PORT filings yet. We sweep new filings monthly.